1763 — China Isotope & Radiation Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapTurnaround

Annual income statement for China Isotope & Radiation, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	C2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4,274	5,144	6,154	6,635	7,575
Cost of Revenue
Gross Profit	2,616	3,242	3,518	3,482	3,683
Selling / General / Administrative Expenses
Research And Development
Operating Interest Expense / Income
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,659	4,366	5,240	5,693	6,469
Operating Profit	615	778	914	942	1,106
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	596	803	921	922	1,045
Provision for Income Taxes
Net Income After Taxes	476	673	755	776	880
Minority Interest
Net Income Before Extraordinary Items
Net Income	214	336	392	371	407
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	214	336	392	371	407
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.681	1.04	1.17	0.674	1.18
Dividends per Share